These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29563772)

  • 1. Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.
    Jin J; Teng C; Li T
    Drug Des Devel Ther; 2018; 12():475-480. PubMed ID: 29563772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.
    Li Q; Yuan Z; Yan H; Wen Z; Zhang R; Cao B
    Clin Ther; 2014 Jul; 36(7):1054-63. PubMed ID: 24986485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
    Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P
    Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
    Prager GW; Oehler L; Gerger A; Mlineritsch B; Andel J; Petzer A; Wilthoner K; Sliwa T; Pichler P; Winder T; Heibl S; Gruenberger B; Laengle F; Hubmann E; Korger M; Pecherstorfer M; Djanani A; Neumann HJ; Philipp-Abbrederis K; Wöll E; Trondl R; Arnold-Schrauf C; Eisterer W
    Eur J Cancer; 2021 Jan; 143():101-112. PubMed ID: 33296830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
    Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
    BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
    Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
    Zhong S; Qie S; Yang L; Yan Q; Ge L; Wang Z
    Medicine (Baltimore); 2017 Jul; 96(30):e7611. PubMed ID: 28746215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
    Tian W; Zhang L; Liu X; Ma X; Wang R
    PLoS One; 2023; 18(3):e0282360. PubMed ID: 36862702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
    Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
    World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
    Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
    Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
    Tu C; Zheng F; Wang JY; Li YY; Qian KQ
    Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.
    Eltawil KM; Renfrew PD; Molinari M
    HPB (Oxford); 2012 Apr; 14(4):260-8. PubMed ID: 22404265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
    Bria E; Milella M; Gelibter A; Cuppone F; Pino MS; Ruggeri EM; Carlini P; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2007 Aug; 110(3):525-33. PubMed ID: 17577216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.